Biotechnology Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

Market Trends and Insights

Accelerated demand for novel biologics and gene-based therapeutics

Demand for novel biologics can deepen as an approved therapy serves multiple defined treatment populations. Genmab reported USD 312 million in global EPKINLY/TEPKINLY net sales in the first half of 2026, up 48% from the first half of 2025. The bispecific antibody is co-developed and co-commercialized with AbbVie and is approved for multiple B-cell malignancies in the United States, Europe, and Japan. Genmab attributed the sales increase to growth across several treatment settings. For biotechnology suppliers, growth across these B-cell treatment settings can increase demand for manufacturing and development support around an already approved antibody.

Rapid cost decline in high-throughput sequencing

Lower sequencing consumables costs can make the breadth of a genomic study less expensive to expand. Illumina reported an approximate USD 200 whole-genome sequencing price in 2025, with a consumables-only list-price basis using a 25B flow cell and 100 Gb per genome. Its comparison placed earlier Solexa instrument sequencing at about USD 1 million per genome. Cheaper sequencing inputs can support larger study designs, and every added genome processed draws on the same reagents and flow cells. For sequencing suppliers, larger studies create a revenue opportunity only when recurring consumables volume more than offsets the lower price per genome.

Government bio-economy stimulus and R&D tax credits

Public support can reduce the private funding required to move biotechnology research toward larger development programs. UK R&D tax relief supports qualifying advances in science or technology, subject to activity, project, and expenditure criteria. In FY 2026, India approved the Biotechnology Industry Research Assistance Council as a Second-Level Fund Manager under its Research, Development and Innovation Fund. For qualifying developers, tax relief can lower research costs, while the Indian appointment creates a biotechnology-focused channel into public R&D finance. Where support reduces the private capital needed per program, developers can commission more development work and the contract services and inputs it consumes.

M&A race for AI-driven drug-discovery platforms

AI-focused acquisitions can expand demand for discovery services by connecting analytical capabilities with laboratory execution and oncology research. In May 2026, IQVIA acquired certain Charles River discovery-services assets, including 5 in vitro drug-discovery sites and a small-molecule AI platform. By March 2026, AstraZeneca identified its Modella AI acquisition alongside Tempus and Pathos partnerships within its multimodal oncology R&D strategy.^[1] These transactions illustrate different routes to combining experimental services with computational capabilities, rather than a single standardized platform model. Commercial value therefore depends on connecting acquired capabilities to a usable research workflow, beyond ownership of an AI model.

Shortage of bioprocessing single-use-systems specialists

Specialist shortages can restrict how quickly biopharmaceutical manufacturers put single-use systems into reliable production. For these operators, replacing hardware does not by itself resolve the work of connecting a disposable assembly with the surrounding process. When integration expertise is scarce, a new production configuration can require more engineering time before it can be used consistently. That constraint can reduce the immediate commercial value of additional capacity, especially when manufacturing plans depend on transferring a process rapidly into production. Manufacturers can build integration expertise alongside equipment deployment, but this requires resources before extra production becomes available. The skilled work needed to make each installation usable can consequently delay capacity activation and the associated demand for production inputs.

Regulatory lag on multi-omic companion diagnostics

Limited standards guidance can make it harder to translate multi-omic companion diagnostics into a defined clinical deployment plan. A 2025 Discover Oncology review identified limited standards guidance for omics-based companion diagnostics integral to personalized nanotherapies. For a developer linking a diagnostic with a personalized treatment, the evidence package needs to connect combined biological measurements with the intended treatment decision. Where that route is unclear, additional clarification and validation work can increase the effort needed to move toward clinical use. This can constrain demand from therapy developers seeking a diagnostic that fits a defined deployment pathway. Therapy-linked development can therefore carry a synchronization cost, with diagnostic readiness affecting when the combined clinical offering can advance toward commercialization.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Biotechnology Market Segment Analysis

Tissue engineering and regeneration accounted for a 20.28% share of the biotechnology market size in 2026. Japan Tissue Engineering reported 111 orders for its autologous cultured cartilage product JACC in April-June 2026 and contracts with 143 facilities as of July 29, 2026.^[2] This Japanese example connects a regenerative product with a defined treatment network, making clinical reach part of its commercialization model. For producers, extending facility relationships can create a route to additional orders alongside the underlying tissue-manufacturing capability. The commercial opportunity therefore depends on connecting specialized production with the treatment locations through which patients can receive the product.

DNA sequencing is forecast to be the fastest-growing technology segment at a 21% CAGR over 2027-2032. Illumina reported USD 775 million in sequencing-consumables revenue in Q2 2026, up 5% year over year on a reported basis. High-throughput volume drove most of that growth, while NovaSeq X installed-base expansion supported consumables use. The company placed more than 95 NovaSeq X instruments that quarter and reported several multi-unit clinical-customer capacity orders, including for new trials. Clinical program expansion can therefore connect instrument demand with the ongoing sequencing work needed to execute research at the required throughput.

Health and red biotechnology represented a 48.21% biotechnology market share in 2026. The 2026 global cell and gene therapy pipeline included 383 active clinical trials, with Phase I and II studies representing 95% of that pipeline. Globally, 17 cell and gene therapy products received approval in the first half of 2026. Providers serving health applications can consequently address clinical-development work and the capabilities needed for commercial supply, with early-stage program support creating a service opportunity alongside manufacturing for approved cell and gene therapies.

The bioinformatics and omics segment is forecast to be the fastest-growing application segment at a 21.6% CAGR over 2027-2032. SOPHiA GENETICS had 542 core genomics customers as of June 30, 2026, compared with 490 a year earlier. A broader customer base can expand the organizational reach of genomic interpretation, creating opportunities around how biological information is used. Industrial processing has a different application focus, illustrated by GenScript Biotech Corporation subsidiary Bestzyme's enzyme development for biofuel, food and beverage, and animal feed uses. These applications favor distinct supplier capabilities, with genomics adoption centered on interpretation and industrial biotechnology addressing defined processing requirements.

Biopharma and biotechnology companies were the largest end-user segment, with a 45.68% share in 2026. Across medicine development, more than 12,900 medicines were in clinical development worldwide in 2025, with three-quarters dedicated to noncommunicable diseases. IQVIA reported that 2025 biopharma funding and large-pharma R&D expenditure were above pre-pandemic levels, although both slowed from 2024. That development activity can create demand for specialized research support before an individual medicine reaches commercial use. Available financing can consequently set the spending pace for a large development-services customer base, separating research-program scale from the timing of supplier revenue.

Academic and research institutes are forecast to be the fastest-growing end-user segment at a 17.1% CAGR over 2027-2032. On September 18, 2026, NIH awarded the University of Southern California funding for a project in which its Keck Genomics Core seeks to acquire an Illumina NovaSeq X Plus system. The award connects institutional funding with a defined instrument-acquisition project, creating a concrete route for research demand. CMOs and CROs form another buyer channel, with Charles River serving a global client base including these organizations through research, drug-development, and manufacturing support services. Academic investment can generate discrete instrument opportunities, while research and manufacturing organizations create a separate channel for specialized service demand.

Biopharmaceuticals were the largest product segment, with a 45.28% share in 2026. Merck reported global Keytruda and Keytruda Qlex sales of USD 31.68 billion in 2025, compared with USD 29.48 billion in 2024. The commercial scale of these antibody-based medicines illustrates how an established therapeutic franchise can concentrate substantial revenue around defined products and their ongoing supply. For biopharmaceutical producers and suppliers, this creates a business case for capabilities that sustain commercial production, with value capture linked to a specific medicine's sales rather than the count of research projects.

The bioinformatics platforms and software segment is forecast to be the fastest-growing product segment at a 15.7% CAGR over 2027-2032. SOPHiA GENETICS performed 115,000 analyses on SOPHiA DDM in Q2 2026, up 22% year over year. A platform's commercial opportunity can grow through repeated analytical work performed within an existing software environment. Bioprocess equipment and consumables follow a different production link, illustrated by Sartorius Stedim Biotech S.A.'s completed June 2025 single-use capacity expansion in Aubagne, France. Scaling analytical usage and expanding consumables production involve different operational investments, allowing suppliers to address digital workflows and physical process capacity through distinct capabilities.

Geography Analysis

North America Biotechnology Market

North America held a 44.56% biotechnology market share in 2026. Amgen, a producer of therapeutics, reported USD 25.7 billion in U.S. product sales across its portfolio in 2025. In May 2026, Micron Biomedical opened a manufacturing facility spanning more than 26,000 square feet in Alpharetta, Georgia, for its dissolvable vaccine and therapeutic technology. The site opened with equipment for design and production at scale, positioning the company for pivotal clinical trials. Established medicine revenues and specialized infrastructure for clinical development create different supplier opportunities, linking the region's commercial base with the manufacturing work required to advance additional therapeutic technologies.

Asia-Pacific Biotechnology Market

Asia-Pacific is forecast to be the fastest-growing region at a 16.4% CAGR over 2027-2032. Singapore's Economic Development Board attracted investments in the biomedical sciences sector in 2025 expected to create 1,775 jobs over the following 5 years. On February 1, 2026, India announced Biopharma SHAKTI to build a domestic production ecosystem for biologics and biosimilars and develop the country as a biopharmaceutical manufacturing hub. For bioprocessing suppliers, the growth opportunity lies in connecting production equipment with bioprocessing workforce and process development, helping investors turn capital commitments into usable manufacturing capabilities.

In Europe, the European Union received 7% of global health-biotechnology venture-capital investment from 2015 through June 2025. In the Middle East, Saudi Arabia's National Biotechnology Strategy, launched in 2024, prioritizes localizing vaccine manufacturing alongside biopharmaceutical manufacturing, genomics and gene therapy research, and agricultural biotechnology. In Africa, WHO Africa and the International Vaccine Institute signed an August 2025 agreement covering vaccine research, trials, regulatory capacity, technology transfer, local manufacturing, and workforce development. In South America, Argentina and Brazil expanded mRNA-platform production capacity through technology transfer and manufacturing partnerships during 2024-2025. The EU figure concerns access to venture capital, while Saudi priorities, the African agreement and capacity expansion in Argentina and Brazil point to opportunities for technology partners building local manufacturing capabilities.

Regulatory Framework and Outlook

Selected jurisdictions are compared from the perspective of developers of well-characterized biosimilar therapeutic proteins seeking entry into additional countries. The comparison centers on reference-product evidence, scientific justification for alternative approaches, and local clinical-study requirements. Japan's May 2026 early-consideration guidance allows case-by-case consideration of efficacy-study omission when product-specific evidence supports biosimilarity. Argentina's 2025 framework for specified well-characterized biological products includes local clinical recruitment and ANMAT-authorized research centers.

Mexico's medium rating and No change outlook reflect the in-force NOM-257-SSA1-2014 requirement for biocomparability studies when applicants rely on a reference medicine. Germany's medium rating and No change outlook reflect the operative EU comparability guideline during consultation through October 31, 2026, on an unadopted replacement. Japan's high rating and No change outlook rest on guidance issued May 18, 2026, permitting efficacy-study omission following case-by-case PMDA consultation. Product-specific quality and PK or PD evidence must establish biosimilarity and show that differences do not affect efficacy, safety or immunogenicity. Saudi Arabia's medium rating and No change outlook reflect SFDA version 2.0, effective August 17, 2025, which calls for standalone quality and manufacturing data plus a comparative quality exercise. South Africa's medium rating and No change outlook reflect SAHPRA version 2, updated December 15, 2025, which allows scientifically and technically justified alternatives and lets the authority request additional information. Argentina's low rating and No change outlook reflect local recruitment and ANMAT-authorized clinical-center requirements under Disposition 1741/2025, in force since March 18, 2025.

Value Chain Stages

The comparison follows biotechnology activities from genetic characterization through cell-culture production to purification and sterile transfer. Illumina supplies sequencing and array instruments, reagents, flow cells, library preparation, analysis tools, and services for research and clinical applications. Thermo Fisher Scientific supplies bioprocessing products spanning culture, bioreactors, purification, fluid management, and technical services. These roles create different earnings opportunities, with analytical platforms monetizing experimental work and process suppliers supporting the transition toward production.

An instrument sale and consumables supply create different revenue exposures for biotechnology suppliers. Repeat consumables purchases link earnings to laboratory or production activity, while technical services can earn fees from matching products with process requirements. Adding production capacity can consequently create supplier earning opportunities across culture, purification, and sterile transfer, extending value capture beyond the initial equipment transaction.

Key Opportunities for Market Participants

The comparison contrasts UK biotechnology investment support with CMS's active Cell and Gene Therapy (CGT) Access Model in the United States, initially focused on sickle-cell gene therapies. The UK government announced the Life Sciences Large Investment Portfolio on April 14, 2026, and its August 2026 guidance sets out eligibility for qualifying medicines companies with UK registration or establishment. Eligibility requires a minimum investment commitment over 3 years, 3 years of audited financial statements, public-fund protections, and at least one eligible project starting within 12 months. The Life Sciences Transformational R&D Investment Fund (TRIF) Pilot targets grant-dependent single-company R&D capital projects in the UK, subject to minimum eligible costs, capped awards, and subsidy controls.

The central opening is access to Medicaid payers for sickle-cell gene therapies through the CGT Access Model. CMS listed 34 state participants on September 30, 2026, including the District of Columbia and Puerto Rico. State Medicaid agencies decide whether to sign the negotiated manufacturer contract. Manufacturers therefore need to turn centrally negotiated terms into agency-level agreements, making each state's acceptance the decisive commercial step in this payer-access pathway.